Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian ... ORPHAZYME A/SJune 28, 2021 GMT Orphazyme A/S Company Registration No. 32266355 Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced 24-month interim results of an open-label extension (OLE) trial, providing efficacy and safety data for its investigational treatment arimoclomol in Niemann-Pick disease type C (NPC) for up to 36 months. ...
Source: apnews.com
